High unmet medical need and strong market potential
  • The indications pursued are all high unmet medical needs
  • The indications pursued combined both blockbuster potential diseases or are orphan diseases
Unique mechanism of action
  • Lead compound: Masitinib, kinase inhibitor selectively targeting the innate immune system through mast cells and macrophages/microglia
  • New compound: AB8939, next generation, synthetic microtubule destabilizer able to overcome multidrug resistance
Strong IP position
  • IP 100% owned by AB Science